Biocryst Pharmaceuticals (BCRX) Total Liabilities (2010 - 2026)

Biocryst Pharmaceuticals' Total Liabilities history runs 17 years deep, the most recent figure standing at $1.0 billion for Q1 2026.

• Quarterly Total Liabilities rose 9.33% year-over-year to $1.0 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.0 billion (up 9.33% YoY) and the FY2025 annual result came in at $633.3 million, down 34.46% from the prior year.
• Total Liabilities was $1.0 billion for Q1 2026 at Biocryst Pharmaceuticals, up from $633.3 million in the prior quarter.
• Across five years, Total Liabilities topped out at $1.0 billion in Q1 2026 and bottomed at $467.9 million in Q1 2024.
• A 5-year average of $696.8 million and a median of $558.6 million in 2022 frame the typical range for Total Liabilities.
• Annual changes were most pronounced in 2022 — Total Liabilities soared 110.19% — and 2025, when it tumbled 34.46%.
• Biocryst Pharmaceuticals' Total Liabilities stood at $550.0 million in 2022, then surged by 76.82% to $972.5 million in 2023, then slipped by 0.63% to $966.4 million in 2024, then tumbled by 34.46% to $633.3 million in 2025, then surged by 60.88% to $1.0 billion in 2026.
• Business Quant data shows BCRX's Total Liabilities at $1.0 billion in Q1 2026, $633.3 million in Q4 2025, and $834.3 million in Q3 2025.